#113 Gout: Uric acid targets, urate lowering therapy, and random questions from social media

Gout management requires a shift from merely suppressing acute symptoms to addressing the underlying hyperuricemia through consistent urate-lowering therapy (ULT). Rheumatologist Dr. Tuhina Neogi emphasizes that clinicians should initiate ULT only after acute flares resolve to avoid exacerbating inflammation through rapid urate fluctuations. Effective management involves starting at low doses of allopurinol—typically 50 to 100 milligrams—and titrating upward every two weeks while monitoring serum urate levels to reach a target below 6 mg/dL. Prophylaxis with colchicine or NSAIDs is essential during the initial titration phase to mitigate flare risks. Relying solely on anti-inflammatory agents for long-term management fails to prevent ongoing urate crystal deposition, which can lead to joint deformity and tophaceous disease. Achieving sustained urate reduction remains the primary strategy for preventing future flares and long-term joint damage.